Private Ocean, LLC Vertex Pharmaceuticals Inc Transaction History

Private Ocean, LLC

$1.08 Billion
Q2 2024

A detailed history of Private Ocean, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Private Ocean, LLC holds 7 shares of VRTX stock, worth $3,231. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$3,231

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	BUY	$392.81 - $485.53 $2,749 - $3,398	7 New	7 $3,000
Q1 2022 Apr 25, 2022	BUY	$221.42 - $260.97 $221 - $260	1 New	1 $0
Q3 2021 Nov 09, 2021	SELL	$181.39 - $202.99 $1,088 - $1,217	-6 Closed	0 $0
Q3 2020 Oct 30, 2020	SELL	$255.65 - $303.1 $8,436 - $10,002	-33 Reduced 84.62%	6 $1,000
Q2 2020 Jul 24, 2020	BUY	$225.48 - $295.8 $7,440 - $9,761	33 Added 550.0%	39 $11,000
Q1 2020 May 06, 2020	SELL	$199.77 - $247.81 $23,772 - $29,489	-119 Reduced 95.2%	6 $1,000
Q4 2019 Feb 05, 2020	BUY	$166.71 - $223.91 $20,838 - $27,988	125 New	125 $28,000
Q1 2018 May 11, 2018	SELL	$151.6 - $177.13 $3,486 - $4,073	-23 Closed	0 $0
Q4 2017 Feb 12, 2018	BUY	$137.28 - $155.55 $3,157 - $3,577	23	23 $3,000

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

Capital World Investors Los Angeles, CA

26.8M
Shares

$12.4 Billion
1.99% of portfolio
Vanguard Group Inc Valley Forge, PA

23.2M
Shares

$10.7 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$9.84 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.8M
Shares

$5.46 Billion
0.23% of portfolio
Capital Research Global Investors Los Angeles, CA

9M
Shares

$4.16 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Ocean, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Private Ocean, LLC with notifications on news.

Account